Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.77 |
| ▸ | CA2 | P00918 | 4/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | CA7 | P43166 | 1/20 | 0.77 |
| ▸ | CA9 | Q16790 | 1/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.77 |
| ▸ | ACR | P10323 | 3/20 | 0.61 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10834543 | 1.00 | CA1 (0.77) | CA1CA2CA12CA7CA9 | |
| SCHEMBL16426422 | 1.00 | CA1 (0.77) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28480069 | 0.98 | CA1 (0.74) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15214832 | 0.95 | CA1 (0.69) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7518320 | 0.92 | CA1 (0.72) | CA1CA2CA12CA7CA9 | |
| SCHEMBL16078330 | 0.90 | MAPT (0.75) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9696072 | 0.90 | HSD17B10 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL688276 | 0.90 | HSD17B10 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL16493489 | 0.90 | HSD17B10 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL740606 | 0.90 | HSD17B10 (0.59) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3268375-B1 | PHOTOCHROMIC THIENOCHROMENE COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3071576-B9 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-3071550-B1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20180051037-A1 | Photochromic Thienochromene Compounds | TRANSITIONS OPTICAL, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9630902-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160209561-A1 | Photochromic Articles That Include Photochromic-Dichroic Materials | TRANSITIONS OPTICAL, INC. | 2016-07-21 | — | — | US | disclosed |
| US-9334439-B2 | Photochromic articles that include photochromic-dichroic materials | TRANSITIONS OPTICAL, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8575097-B2 | Exendin variant and conjugate thereof | PEGBIO CO., LTD. (CN) | 2013-11-05 | — | — | US | disclosed |
| US-8455061-B2 | Optically active compound having polymerizable group and its polymer | JNC CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120196795-A1 | NOVEL EXENDIN VARIANT AND CONJUGATE THEREOF | PEGBIO CO., LTD. (CN) | 2012-08-02 | — | — | US | disclosed |
| EP-2423223-A1 | NOVEL EXENDIN VARIANT AND CONJUGATE THEREOF | Pegbio Co., Ltd. (CN) | 2012-02-29 | — | — | EP | disclosed |
| EP-1613317-A1 | COMBINATION OF A MACROLIDE AND A LOCAL ANESTHETIC FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087144-A1 | COMBINATION OF A MACROLIDE AND A LOCAL ANESTHETIC FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| EP-0352293-A4 | NON-CRYSTALLINE MINOXIDIL COMPOSITION AND METHOD OF APPLICATION | — | 1991-03-20 | — | — | EP | disclosed |
| EP-0352293-A1 | NON-CRYSTALLINE MINOXIDIL COMPOSITION AND METHOD OF APPLICATION | LIPOSOME TECHNOLOGY, INC. (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4828837-A | Non-crystalline minoxidil composition, its production and application | LIPOSOME TECHNOLOGY, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| WO-1988007362-A1 | NON-CRYSTALLINE MINOXIDIL COMPOSITION AND METHOD OF APPLICATION | LIPOSOME TECHNOLOGY, INC. (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | CA1 3567/4885CA2 1663/4885CA12 2526/4885 |
| US-20120196795-A1 | NOVEL EXENDIN VARIANT AND CONJUGATE THEREOF | GLP1R, IAPP, GIPR | CA1 4704/4885CA2 4112/4885CA12 1780/4885 |
| US-20180051037-A1 | Photochromic Thienochromene Compounds | CRY1, CRY2, TERT | CA1 4264/4885CA2 3806/4885CA12 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.